Latest Breaking News On - Global head of oncology development - Page 1 : comparemela.com

NATALEE Data Shows Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Early Breast Cancer

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

United statesSebastian kaulitzkiDenisea yardleyJeff legosAimee keeganSarah cannon research instituteBreast cancer research executive committeeGlobal head of oncology developmentEuropean medicines agencyAmerican society of clinical oncologyBreast cancer researchPharmacy timesClinical oncologyAnnual meetingGlobal headOncology development

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaFrance generalUnited statesSan antonioSloan simpsonIsabella zinckSatoshi sugimotoParag mahantiNicole zinsli sommMarlena abdinoorJeff legosJonathan grahamMichael meoImke kappesDenisea yardleyEuropean society of medical oncology congress

New immuno-oncology treatment approved for endometrial cancer

New immuno-oncology treatment approved for endometrial cancer
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Hesham abdullahSociety of gynecologic oncologyDrug administrationGlobal head of oncology developmentEuropean society for medical oncologySenior vice presidentGlobal headOncology developmentEuropean societyMedical oncologyVirtual plenaryGynecologic oncologyAnnual meetingNew england journalBiologics license applicationBreakthrough therapy

GSK (GSK) announces Jemperli plus chemotherapy approved in US as first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

GSK (GSK) announces Jemperli plus chemotherapy approved in US as first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMatthew powellHesham abdullahWenora johnsonDrug administrationOur risk of cancer empoweredEuropean medicines agencyOncology centerWashington university school of medicineEuropean society for medical oncologySociety of gynecologic oncologyDivision of gynecologic oncologyGlobal head of oncology developmentBiologics license applicationPriority reviewPrescription drug user fee act

GSK plc: Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

GSK plc: Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomUnited kingdom generalCity ofTreasure islandCamilla campbellLyndsay meyerMatthew powellCerner envizaHesham abdullahSteph mountifieldJeff mclaughlinNick stoneJosh williamsCerner enviza cancermpactMadison goring